Bowen Acquisition Enters Into Merger Agreement With Shenzhen Qianzhi Biotech Company
Bowen Acquisition Enters Into Merger Agreement With Shenzhen Qianzhi Biotech Company
Pursuant to the Merger Agreement, BOWN's wholly owned subsidiary, Bowen Merger Sub, a Cayman Islands exempted company, will merge (the "Merger" or the "Business Combination") with and into Qianzhi Group Holding (Cayman) Limited, parent of Qianzhi BioTech and an exempted company incorporated with limited liability in the Cayman Islands ("NewCo"), with NewCo being the surviving company of the Merger and becoming a wholly-owned subsidiary of BOWN. In connection with the Merger, the NewCo Shareholders will receive an aggregate of 7,246,377 ordinary shares of BOWN and have the right to receive up to an additional 1,400,000 ordinary shares of BOWN upon the achievement of certain earnout targets as provided for in the Merger Agreement.
根據合併協議，BOWN的全資子公司開曼群島豁免公司Bowen Merger Sub將與千智集團控股（開曼）有限公司合併（“合併” 或 “業務合併”），後者是千智生物的母公司，也是一家在開曼群島註冊成立的有限責任公司（“NewCo”），而NewCo是合併的倖存公司，成爲BO的全資子公司 WN。與合併有關的是，NewCo股東將獲得總計7,246,377股BOWN普通股，並有權在實現合併協議中規定的某些收益目標後額外獲得最多140萬股BOWN普通股。
譯文內容由第三人軟體翻譯。